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ABSTRACT 21 
The aim of this work was to elucidate the role of the secondary metabolites produced by 22 
B. amyloliquefaciens BUZ-14 against B. cinerea, M. fructicola, M. laxa, P. digitatum, 23 
P. italicum and P. expansum both in vitro and in planta. The entire cell free supernatant 24 
(CFS) and the lipopeptide fraction (LPF) showed similar antifungal activities, 25 
completely inhibiting all the fungi at dilutions of 1:24 or even lower, whereas the non-26 
butanolic fraction (NBF) barely inhibited the fungi. However, when the LPF and CFS 27 
were applied on fruit, only brown rot in peaches and blue rot in apples was totally 28 
inhibited. The main families of metabolites in the LPF were iturin A, fengycin and 29 
surfactin with maximum concentrations of 407, 853 and 658 µg mL-1, respectively. 30 
Subsequently, a TLC-bioautography revealed iturin A as the key metabolite in the 31 
inhibitions and allowed us to establish in vivo MICs of 16.9 and 33.9 µg mL-1 for 32 
Monilinia species and P. expansum, respectively. The application of 24 h-old BUZ-14 33 
cultures supressed brown rot in peaches and also blue rot in apples but failed to inhibit 34 
the other diseases. However, BUZ-14 was only able to grow and produce iturin A in 35 
peaches so we can deduce that the amount of iturin A brought with the cultures (36 ± 14 36 
µg mL-1) could be enough to control both diseases. The strong antifungal activity of the 37 
iturin A present in the BUZ-14 CFS suggests that it could be successfully used for 38 
postharvest disease control. However, future research is necessary to maximize the 39 
iturin A production by B. amyloliquefaciens BUZ-14 in order to optimize a commercial 40 
application. 41 
 42 
Keywords: biocontrol, Monilinia spp., P. expansum, lipopeptides, iturin A.  43 
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1. Introduction 45 
Nowadays, pesticides and fungicides are the main system used to control biotic agents 46 
responsible for pre- and postharvest rot. However, current legislation covering 47 
pesticides has become stricter by reducing the MRLs (Maximum Residue Limits) in 48 
plants and forbidding numerous effective fungicides because of the development of 49 
fungicide-resistant strains of pathogens, the detection of chemical residues in the food 50 
chain and their toxicity for human health and the environment. Therefore, new 51 
alternatives such as biological control by using natural antagonistic microorganisms are 52 
currently being studied in depth (Chung et al., 2008; Zhao et al., 2013). Several wild-53 
type Bacillus subtilis and B. amyloliquefaciens strains have been reported for their 54 
effectiveness in the biocontrol of multiple plant diseases caused by soil borne and 55 
postharvest pathogens (Alvarez et al., 2012; Arguelles-Arias et al., 2009; Arrebola et al., 56 
2009; Calvo et al., 2017; Chen et al., 2016; Chen et al., 2009; Chung et al., 2008; Gong 57 
et al., 2015; Hinarejos et al., 2016; Romero et al., 2007; Toral et al., 2018; Torres et al., 58 
2017; Touré et al., 2004; Yánez-Mendizábal et al., 2012). Most authors sustain that 59 
antibiosis is the main mechanism of action against pathogens since some Bacillus 60 
strains are capable of producing a substantial number of antifungal secondary 61 
metabolites, especially the non-ribosomally synthesised cyclic lipopeptides (Alvarez et 62 
al., 2012; Torres et al., 2017; Veras et al., 2016). These substances are divided into three 63 
families according to their structure: surfactin, fengycin and iturin. The chemical 64 
structure has previously been studied by numerous authors, regarding the type and 65 
sequence of amino acid residues, the nature of the peptide and length and branching of 66 
the fatty acid chain (Hinarejos et al., 2016; Ongena and Jacques, 2008; Stein, 2005; 67 
Torres et al., 2016; Xu et al., 2013). The mechanism of direct antibiosis associated with 68 
Bacillus strains against foliar and postharvest diseases has been attributed mostly to 69 
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iturins and fengycins (Arrebola et al., 2010; Romero et al., 2007; Yánez-Mendizábal et 70 
al., 2012) although other metabolites such as polyketides (Chen et al., 2006; 2009), 71 
siderophores (Li et al., 2014), bacteriocins (Ayed et al., 2015) and volatile organic 72 
compounds (VOCs) (Gotor-Vila et al., 2017) must not be forgotten. These metabolites 73 
and compounds can be produced by the biological control agent (BCA) in the 74 
formulation prior to the application with the mechanism of action based on a direct 75 
antibiosis. Otherwise, these compounds could be produced directly in the plant while 76 
the BCA is growing in situ (Touré et al., 2004). The latter option would increase the 77 
possibility of success because the mechanisms of action such as competition for 78 
nutrients or colonization would be taken into account, as well as the fact that the direct 79 
inhibition provoked by the metabolites could be stronger. Nevertheless, direct antibiosis 80 
has not only been cited as a mechanism for controlling disease since it has also been 81 
demonstrated that most of the metabolites produced by B. subtilis or B. 82 
amyloliquefaciens strains can induce systemic resistances (ISR) in plants (Cawoy et al., 83 
2014; Choudhary and Johri, 2009; Ryu et al., 2004). The role of lipopeptides from B. 84 
subtilis (Ongena and Jacques, 2008; Ongena et al., 2005; 2007) and from B. 85 
amyloliquefaciens (Chowdhury et al., 2015) has been studied on various plants for 86 
inducing immune responses. As an example, fengycins from B. subtilis M4 could be 87 
involved in the systemic resistance-eliciting effect of this strain, as these molecules may 88 
induce the synthesis of plant phenolics involved in or derived from the defence-related 89 
phenylpropanoid metabolism (Ongena et al., 2005).   90 
The aim of this work was to elucidate the role of the secondary metabolites produced by 91 
B. amyloliquefaciens BUZ-14 against B. cinerea, M. fructicola, M. laxa, P. digitatum, 92 
P. italicum and P. expansum both in vitro and in planta. For this purpose, 4 steps were 93 
addressed (i) characterisation of the in vitro and in vivo antifungal activity of CFS, LPF 94 
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and NBF through the determination of their MICs, (ii) identifying and quantifying the 95 
lipopeptides produced (iii) determining the lipopeptide responsible for the antagonistic 96 
activity and (iv) quantifying the lipopeptide production on fruit. 97 
2. Materials and methods 98 
2.1 Fungal pathogens 99 
The fungal pathogen strains used in this study were Botrytis cinerea VG 1, Monilinia 100 
fructicola VG 104, M. laxa VG 105, Penicillium digitatum VG 20, P. expansum CECT 101 
20140 and P. italicum VG 101. They were obtained from the Plant Food Research 102 
Group culture collection (Zaragoza, Spain) and incubated on potato dextrose agar 103 
(PDA) (Oxoid Ltd; Basingstoke, Hampshire, England) and potato dextrose broth (PDB). 104 
2.2 Fruit samples 105 
In this study different fruits were used depending on the diseases tested. Peaches (cv. 106 
Calante), strawberries (cv. Fortuna), mandarins (cv. Clementina) and apples (cv. Golden 107 
Delicious) were used for Monilinia spp., B. cinerea, P. digitatum and P. italicum, and P. 108 
expansum inoculations, respectively. All fruits were collected from local packing 109 
greenhouses and were grown in different areas of Spain (La Almunia de Doña Godina, 110 
Tarragona and Teruel). Prior to the experiments, all fruits were surface-disinfected by 111 
immersion for 2 min in 1% sodium hypochlorite, rinsed with tap water, and allowed to 112 
air-dry at room temperature (20 ºC). 113 
2.3 Bacterial strain identification 114 
B. amyloliquefaciens BUZ-14 was identified through a phylogenetic analysis of its 16S 115 
rDNA and partial gyrase gene sequences gyrB. The genomic DNA of BUZ-14 was 116 
extracted using a FavorPrep Tissue Genomic DNA Extraction Mini Kit (Favorgen 117 
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Biotech Corporation, Taiwan). The 16S rDNA was amplified by PCR using the 118 
universal primers 8F (5′-AGA GTT TGA TCC TGG CTC AG -3′) and 1492R (5′-CGG 119 
TTA CCT TGT TAC GAC TT -3′) (Microsynth AG, Switzerland). Part of the gyrB 120 
sequence was amplified with gyrB-BUZ-14F (5′-ACC GGA ACG ATT ACG CAC TT -121 
3′) and gyrB-BUZ-14R (5′- AGG GTC CAT TGT CGT TTC CC -3′) (Microsynth AG, 122 
Switzerland) primers previously designed with Primer3 v. 0.4.0 software (Untergasser 123 
et al., 2007), based on the type strain Bacillus amyloliquefaciens FZB42.  124 
2.4 In vitro antifungal activity of the cell-free supernatant (CFS), non-butanolic fraction 125 
(NBF) and lipopeptide fraction (LPF) from B. amyloliquefaciens BUZ-14 against 126 
fungal pathogens 127 
The antifungal activity of CFS, NBF and LPF was tested in vitro against the fungal 128 
pathogens cited in section 2.1. BUZ-14 was incubated in 863 medium (20 g L-1 129 
dextrose, 10 g L-1 peptone, 10 g L-1 yeast extract) at 30 ºC for 96 h. The separation of 130 
supernatant from cells was done by centrifugation (Megafuge Heraeus 1.0R, Thermo 131 
Fisher, UK) at 4000 x g for 10 min in 50 mL falcon tubes containing 25 mL of bacterial 132 
culture. The supernatant was decanted and consecutively autoclaved at 121 ºC for 15 133 
min. Lipopeptide extraction was carried out following a method described in the 134 
bibliography (Yazgan et al., 2001), by which n-butanol was added to the supernatant 135 
(ratio 1:4) and the sample was centrifuged at 4000 x g in order to separate the butanolic 136 
layer containing all the lipopeptides. On the other hand, the non-butanolic layer 137 
contained the rest of the substances produced by BUZ-14 in the conditions explained 138 
above. Finally, each fraction was dried using a rotary evaporator. The three fractions 139 
were processed in order to maintain the same ratio of concentration throughout the 140 
experiment. The fractions were stored at -80 ºC until their laboratory use. 141 
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For the in vitro inhibition tests, 48-well plates were used. The MIC (Minimal Inhibitory 142 
Concentration) of each fraction was found by diluting the antimicrobial into PDB 143 
medium. Five hundred µL of the medium were added into the well, followed by 30 µL 144 
of each pathogen (104 conidia mL-1). Finally, different quantities of LPF, NBF or CFS 145 
were transferred until obtaining 1:6, 1:12, 1:24, 1:48, 1:80 and 1:100 dilutions. A 146 
positive control without the antimicrobial fraction and a negative control without the 147 
pathogen were also included. The plates were incubated at 25 ºC for 7 days. The results 148 
were obtained by observing visually the presence (growth) or absence (non-growth) of 149 
fungi. Five replicates per pathogen were conducted and the experiment was done in 150 
three independent days.  151 
2.5 Antifungal activity of CFS and LPF from BUZ-14 on fruit 152 
In this study, the antimicrobial activity on fruit of the CFS and LPF obtained from 96 h-153 
old cultures was assessed. Fruit were wounded with a sterile tip and 10 µL of the 154 
respective pathogen (104 conidia mL-1) was inoculated. After 1 hour of absorption of the 155 
conidial suspensions, the CFS and LPF were inoculated at 1:6, 1:12, 1:24 and 1:48 156 
dilutions. The fruits were stored at 20 ºC for 5 days and 80 % R.H. (relative humidity). 157 
The severity was evaluated as a percentage of reduction of the disease by measuring the 158 
lesion diameter in treated fruits and the control. Fifteen fruits per pathogen and 159 
treatment (one wound per fruit) were disposed. The entire experiment was repeated in 160 
three different days. 161 
2.6 Isolation and identification of antifungal lipopeptides 162 
In order to find out the lipopeptides responsible for direct antibiosis, a Thin Layer 163 
Chromatography (TLC) followed by bioautography was performed and the active 164 
fractions identified by Liquid Chromatography-Electrospray Ionization-Mass 165 
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Spectrometry (LC–ESI-MSE) analysis. The lipopeptides present in the LPF were also 166 
identified and quantified. 167 
2.6.1 Thin Layer Chromatography (TLC) and bioautography 168 
Ten µL aliquots from the lipopeptide fraction produced by BUZ-14 and the reference 169 
strain B. amyloliquefaciens FZB42 after 96 h of incubation at 30 ºC were spotted onto 170 
TLC aluminium sheets coated with silica gel 60 F254 5 x10 cm (Sigma Aldrich, Spain). 171 
The sheets were placed in a separation chamber containing chloroform/methanol/water 172 
(65:25:4, v/v/v) as mobile phase, following the protocol proposed by Razafindralambo 173 
et al. (1993). The spots were detected under 254 nm UV light and their retention factor 174 
(Rf) determined. The strain FZB42, purchased from the DSMZ collection (Germany), 175 
was used as a bacillomycin producer since no commercial standard was found.  176 
The bioautography was performed as described by Chen et al. (2016) in order to 177 
identify the family of lipopeptides responsible for fungal inhibition. Briefly, the TLC 178 
plates were placed in 90 x 90 mm Petri plates and covered with melted PDA medium 179 
inoculated with pathogens at 1-3 x 104 conidia mL-1. The moulds tested were those cited 180 
in Section 2.1. The plates were incubated at 25 ºC for 7 days and the Rf of the active 181 
fraction was determined. Then, the Rf was compared to that in the previously conducted 182 
TLC and the active lipopeptide was established. Moreover, each antifungal compound 183 
was scraped from the silica gel and extracted with 2 mL of methanol under magnetic 184 
conditions stirred at 300 rpm overnight. Afterwards, the sample was centrifugated at 185 
10000 x g and the resulting supernatant was subjected to Liquid Chromatography-Mass 186 
Spectrometry analysis as detailed in section 2.6.3. Five replicates were used per 187 
pathogen and the experiment was repeated on three different days.  188 
2.6.2 High Performance Liquid Chromatography Diode-Array Detector (HPLC-DAD)  189 
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The lipopeptides were identified and quantified after 24, 48, 72 96 and 120 h of 190 
incubation using an Agilent 1100 liquid chromatograph coupled to an Agilent 1200 191 
Series DAD detector (Agilent, USA) with a Lichrospher RP18 column, 5µm 250x4 mm 192 
(Sigma Aldrich, Spain). The mobile phase A was 0.1% formic acid in acetonitrile, and 193 
mobile phase B was 0.1% formic acid in Milli-Q water. The flow rate was 1 mL min-1 194 
and the temperature of the column was set at 30 ºC. The gradient started at 35% A and 195 
was held for 8 min. From 8 min to 10 min the gradient was raised to 40% A and kept for 196 
15 min. Then, the gradient was raised to 80% for 5 min and held at 80% for 15 min. 197 
Finally, the gradient reached 100% for 5 min and returned to the initial conditions 198 
during 5 min. The total run time was 60 min. Lipopeptides were monitored at 214 nm. 199 
The analytical standards were iturin A (purity ≥95%), Chemical Abstract Service 200 
identification number: 52229-90-0; surfactin ≥ 98%, 24730-31-2 and fengycin ≥ 90%, 201 
102577-03-7. All of them were purchased from Sigma Aldrich, Spain.  These analytical 202 
standards were used for the identification and quantification of the samples. The 203 
calibration curve was determined by using standard solutions containing 20, 100, 400, 204 
1000 and 1400 µg mL-1 of each compound. In all cases, the solutions were injected in 205 
the chromatograph three times and the extraction process was carried out on three 206 
separate days.    207 
2.6.3 Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (LC–ESI-208 
MSE) analysis 209 
The lipopeptide fractions obtained after 96 h of incubation time were also subjected to 210 
an LC–ESI-MSE analysis to identify the different isoforms of each lipopeptide as well 211 
as the compounds which exhibited antifungal activity on the TLC plates. For this 212 
purpose, an Acquity UPLC H-CLASS system supplied by Waters (Milford, USA) was 213 
used. Chromatographic separation was performed on a Waters Acquity UPLC BEH C18 214 
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(1.7 µm, 2.1 mm×100 mm) at 40 ºC. Mobile phase A was MilliQ-water with 0.1% 215 
formic acid and mobile phase B acetonitrile with 0.1 % formic acid. The flow rate was 216 
0.50 ml·min−1 and the injection volume 10 µL. The time program for multi-step gradient 217 
was 0–5 min, 70% A-30 % B to 5 % A-95 % B, 5–10.10 min, 5 % A-95 % B to 70 % 218 
A-30 %. The run time was 12 min and the sample temperature was set at 10 ºC. Mass 219 
spectra were acquired using a time-of-flight (TOF) MS Synapt G2 High Definition 220 
Mass Spectrometer supplied by Waters (Milford, USA). Nitrogen was used as a 221 
desolvation gas at 800 L·h−1 flow. The cone gas flow was 40 L·h−1. The ion source 222 
parameters were corona current 3 µA, sample cone 40 V and desolvation gas 223 
temperature 500 °C. Electrospray ionization mode (ESI) in positive polarity was 224 
selected; the source temperature was 120 ºC. The scan time was 1 s and the mass range 225 
considered was m/z 100–2400. MassLynx v4.1 software supplied by Waters (Milford, 226 
USA) was used for the analysis of the results obtained, which considers the isotopic 227 
model and the elemental composition. 228 
2.7 BUZ-14 growth and iturin A production on fruit  229 
The growth curves of BUZ-14 and the production of iturin A in fruit were determined. 230 
Fruits were wounded as described in section 2.5 and 10 µL of the respective pathogen 231 
(104 conidia mL-1) was inoculated. After 1 hour at room temperature to favour the 232 
absorption of the conidia suspension, a 24 h-old culture (10 µL) of B. amyloliquefaciens 233 
(108 CFU mL-1) was inoculated and the fruit was stored at 20 ºC and 80 % R.H. for 7 234 
days. The percentage of reduction of the fungal growth was then recorded. To determine 235 
the growth of the BCA, 10 grams of fruit wound was cut through with a sterile scalpel. 236 
The fruit plugs were placed in filter blender bags and diluted 1:5 with 0.1% sterile 237 
peptone water. The mixture was homogenized in a Stomacher 400 Circulator laboratory 238 
blender (Seward Laboratory, London, England) for 120 s at 260 rpm and the resulting 239 
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suspension was diluted, plated on TSA plates and counted after 24 h at 30 ºC. The 240 
extraction of lipopeptides was carried out in the homogenate following the procedure 241 
described in section 2.4. The subsequent quantification was conducted with the HPLC-242 
DAD (see section 2.6.2) and the amount of lipopeptides quantified and expressed in µg 243 
g-1 of fruit tissue. Fifteen fruits per fungal pathogen were used as replicates and the 244 
experiment was carried out on 3 separate days. 245 
2.8 Statistical analysis 246 
Data were statistically treated by t-student analysis using SPSS software (SPSS statistics 247 
22.0). The statistical differences between means of different treatments were assessed at 248 
P < 0.05. 249 
3. Results and discussion 250 
3.1 B. amyloliquefaciens BUZ-14 strain phylogenetic identification 251 
The bacterial strain tested in this study has been previously identified by Calvo et al. 252 
(2017) as Bacillus amyloliquefaciens and named BUZ-14. However, due to the genetic 253 
similarity among species of the Bacillus group and the several recently renamed 254 
subspecies, we have made a more in-depth study of its identification. B. 255 
amyloliquefaciens BUZ-14 16S rDNA and gyrB sequences were obtained and deposited 256 
in Genbank with accession numbers MF461174 for 16S rDNA and MF770248 for gyrB. 257 
The sequences were processed using the BLAST tool provided by Genbank. The 258 
information obtained from these results enabled a phylogenetic tree to be constructed 259 
(Supplemental files: Figure 1 and 2). In order to achieve a more reliable level of 260 
identification, the subunit B protein of DNA gyrase (gyrB) was subjected to sequencing 261 
(Hossain et al., 2015; Wang et al., 2007). This strain was designated as B. 262 
amyloliquefaciens subsp. plantarum BUZ-14, although recent studies have proposed 263 
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including this classification within B. velezensis together with other Bacillus species 264 
(Dunlap et al. 2016). Plant-associated B. amyloliquefaciens strains belonging to subsp. 265 
plantarum are distinguished from others such as subsp. siamensis or amyloliquefaciens 266 
by their capacity to stimulate plant growth, to colonize the plant rhizosphere and to 267 
suppress competing phytopathogenic bacteria and fungi. 268 
3.2 In vitro antifungal activity of the cell-free supernatant (CFS), non-butanolic fraction 269 
(NBF) and lipopeptide fraction (LPF) from B. amyloliquefaciens BUZ-14 against 270 
fungal pathogens 271 
The aim of this assay was to characterize the antifungal activity of BUZ-14 secondary 272 
metabolites by establishing differences among the CFS, the NBF and the LPF. The 273 
activity of the three fractions was evaluated in liquid medium after 96 h of incubation at 274 
30 ºC in 863 broth against the fungal pathogens cited in section 2.1. In this study, we 275 
have separated the lipopeptides (LPF) from other compounds (NBF) and we have 276 
observed that all the phytopathogens were greatly inhibited by the LPF (Table 1). The 277 
results showed that the NBF was barely effective against the six postharvest fungal 278 
pathogens tested. However, the LPF achieved the inhibition of all the pathogens in a 279 
1:24 dilution for B. cinerea and P. digitatum, 1:48 for M. fructicola, P. italicum and P. 280 
expansum and with M. laxa as the most susceptible species with a MIC below 1:100. 281 
The activity observed in vitro in the CFS is related to all the active compounds 282 
produced by BUZ-14, so a maximum inhibition was expected. However, the MICs 283 
obtained were only slightly higher or even the same as those of the LPF, supporting the 284 
idea that the antifungal activity lies with the lipopeptides. Nevertheless, not all the 285 
pathogens needed the same concentration, and it was observed that M. laxa was much 286 
more sensitive to these compounds. It is known that the same substance can exert 287 
different antimicrobial activity depending on the target microorganism (Ambrico and 288 
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Trupo, 2017; Chen et al., 2009; Ji et al., 2013). Accordingly, Yánez-Mendizábal et al. 289 
(2012) identified a fengycin-like lipopeptide as the main metabolite responsible for 290 
Monilinia spp. inhibition by B. subtilis CPA-8. However, Zhao et al. (2013) determined 291 
that in the case of the Bacillus BH072 strain, iturin A was the main inhibitor of B. 292 
cinerea. Additionally, these kinds of plant-growth-promoting bacteria produce several 293 
non-ribosomal polyketides and lipopeptides, apart from iron-siderophores, bacteriocins 294 
and volatile compounds with relevant antifungal activity (Alvarez et al., 2012; 295 
Arguelles-Arias et al., 2009; Ayed et al., 2015; Borriss et al., 2011; Romero et al., 296 
2007).  297 
3.3 LPF and CFS antifungal activity on fruit  298 
The substantial activity demonstrated by the metabolites produced by BUZ-14 against 299 
fungal pathogens in vitro does not ensure the same effect on a food matrix. Usually, 300 
MICs are significantly higher in vivo since the fungi efficiently used the nutrients 301 
available in the fruit while the low pH, acids and phenols are all barriers to the 302 
development of many bacteria. Therefore, the LPF and CFS were also tested in fruit 303 
against the six postharvest pathogens used in the study. In this context, the NBF was 304 
discarded due to the poor activity observed in the in vitro tests. The results of the LPF 305 
and CFS antifungal activity are shown in Table 2. As can be observed, the LPF 306 
controlled brown rot caused by M. fructicola and M. laxa in peaches even by 20-fold 307 
dilution (1:24). However, a 10-fold dilution (1:12) was necessary to prevent blue rot in 308 
apples. The efficacy against B. cinerea was also high, reducing the disease in strawberry 309 
by 72% at a 1:6 proportion. However, blue and green rot in mandarins was barely 310 
controlled at any concentration. No significant differences were observed between the 311 
fractions in most of the pathogens, although the CFS was slightly better at a 1:48 ratio 312 
against both Monilinia species.  313 
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3.4 Isolation and identification of lipopeptides from B. amyloliquefaciens BUZ-14  314 
In order to determine the families of lipopeptides present in the LPF after 96 h of 315 
incubation in 863 medium, a TLC analysis of BUZ-14 and FZB42 (as a bacillomycin 316 
producer) was performed and their Rf established. Briefly, marks of all the families 317 
were observed in the TLC under UV-light. However, no differences were observed 318 
between the two BCAs since the same spots and Rf were detected. To identify the 319 
active compounds from the lipopeptide fraction of both BCAs, a TLC-bioautography 320 
was developed. Only one active fraction was found in BUZ-14 (0.26) resulting in a very 321 
strong inhibition against all the pathogens tested (Figure 1). According to the literature, 322 
this Rf should belong to mycosubtilin, a typical lipopeptide of the species B. subtilis 323 
with a large antifungal spectrum range (Duitman et al., 1999). However, the 324 
mycosubtilin gene was neither found in BUZ-14 (Supplemental Table 1) nor later 325 
detected by HPLC, so this option was discarded. Arrebola et al. (2010) found that iturin 326 
A produced by B. amyloliquefaciens PPCB004 appeared at a Rf of 0.3 but Yánez-327 
Mendizábal et al. (2012) obtained the same Rf for bacillomycin D. These findings, 328 
added to the fact that FZB42 produces another lipopeptide with a Rf of 0.3 329 
(bacillomycin), make it impossible to elucidate by TLC whether BUZ-14 was an iturin 330 
A or a bacillomycin D producer. Moreover, FZB42 did not show inhibition in the 331 
bioautography against any pathogen, indicating that both metabolites developed in the 332 
TLC at the same Rf could be different. 333 
The lipopeptides from both BCAs were identified by HPLC-DAD. By comparing these 334 
metabolites with the analytical standards, three groups of peaks were observed 335 
(Supplemental Figure 3A), corresponding to iturin A, fengycin and surfactin, 336 
respectively for BUZ-14, although neither bacillomycin or nor mycosubtilin were 337 
detected.  However, as expected, no iturin A was detected in the FZB42 chromatogram 338 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
(Supplemental Figure 3B). Even so, additional information was required in order to 339 
confirm the results, so more sensitive chromatographic analyses using LC-MS-MSE 340 
were carried out. The previously obtained LPF containing the lipopeptide families and 341 
the active fraction (Rf=0.26) scraped from TLC plates were subjected to mass 342 
spectrometry analysis. The molecular masses were monitored in the m/z range of 100–343 
2400 uma. By analysing the lipopeptide profiles after 96 h of BUZ incubation, three 344 
isoforms of surfactin (C13, C14 and C15), four of fengycins (C16A, C16B, C17A and 345 
C17B) and four of iturins (C13, C14, C15 and C16) were identified (Table 3).  The m/z 346 
obtained of the active compound scraped from the TLC-bioautography corresponded to 347 
iturin A (Hiradate et al., 2002; Yu et al., 2002; Ongena and Jacques, 2008; Athukorala 348 
et al., 2009). In addition, this result was confirmed by injecting the iturin A standard in 349 
the LC-MS-MSE. It was observed that both the active fraction and the standard shared 350 
the same retention times and masses for the four peaks detected: 1.76 min for m/z 351 
1043.5562; 1.98 min for m/z 1057.5704; 2.33 min for m/z 1071.5900 and 2.53 min for 352 
m/z 1085.5981. Finally, comparisons of MSE spectra of the active fraction and the 353 
commercial standard of iturin A confirmed its identification (Figure 2) and we could 354 
establish iturin A as the main lipopeptide responsible for antifungal activity against 355 
these postharvest moulds.  356 
3.4.3 Lipopeptide production curve 357 
The concentration of the compounds during the incubation time in 863 medium was 358 
also determined (Figure 3). After 24 hours of incubation, iturin A reached 36.3 µg mL-1 359 
but surfactin and fengycin were not detected. The amount of iturin A increased 360 
progressively reaching 407 µg mL-1 after 96 h of incubation. Fengycin also achieved the 361 
highest concentration after 96 h of incubation with 853 µg mL-1. Otherwise, the top 362 
peak of surfactin was obtained after 72 h with 658 µg mL-1. After 72 h of incubation of 363 
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B. subtilis GA1 in a culture medium optimized for lipopeptide production (named Opt), 364 
Touré et al. (2004) obtained concentrations of fengycins, iturins and surfactins of 520, 365 
460 and 340 µg·mL-1, respectively. Also, Ambrico and Trupo (2017) in High Medium 366 
Broth (HMB) achieved the highest amount of iturin, 422 mg L-1, from B. subtilis ET-1 367 
after 50 h of incubation. Thus, the incubation time is an essential factor in the 368 
production of secondary metabolites together with the culture medium. The production 369 
process of biocontrol agents is an essential step for their commercial use as bioproducts. 370 
A key factor to consider is the development of an economical culture medium that 371 
supports both the production of large commercial amounts of the BCA and its 372 
metabolites at a low price. In our case, the 863 medium achieved a notable lipopeptide 373 
production and although it cannot really be considered a low cost medium, it is very 374 
simple as it has 3 ingredients only. However, considering that B. amyloliquefaciens may 375 
grow and synthesize its metabolites from cheap substrates, our future research will 376 
focus on finding a low cost medium based on commercial products or by-products from 377 
the food industry that can provide maximum BUZ-14 growth and lipopeptide 378 
production in large scale production processes. 379 
3.5. Correlation between Iturin A concentration and antifungal activity 380 
Finally, relating the production of iturin A in BUZ-14 cultures (Figure 3) with the data 381 
of LPF inhibitions in vitro (Table 1) and in vivo (Table 2) we can establish the MICs of 382 
iturin A (Table 4). Thus, the MICs in vitro of iturin A (µg mL-1) were as follows: 4.1 for 383 
M. laxa, 8.5 for M. fructicola, P. italicum and P. expansum and 16.9 for B. cinerea and 384 
P. digitatum (Table 4). These MICs in vitro are in partial agreement with those of 385 
Ambrico and Trupo (2017) who determined a MIC of iturin A of 6 and 3 µg mL-1 for P. 386 
digitatum and B. cinerea, respectively, in a solid medium in vitro test. These 387 
discrepancies could be explained by several factors such as the different in vitro test 388 
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used (solid and liquid medium), the differences in the type and percentages of the 389 
isoforms of iturin A produced by the BCA strains, and the different phytopathogen 390 
strains used. However, the MICs of iturin A in vivo were only achieved in Monilinia 391 
spp. and P. expansum (16.9 and 33.9 µg mL-1 respectively) (Table 4). The growth of the 392 
rest of the pathogens were reduced but their respective diseases were manifested (Table 393 
2) since their MICs were higher than the concentration tested in this study (67.8 µg mL-394 
1
 ).   395 
3.6 BUZ-14 growth and iturin A production in fruit 396 
The results showed that the 24 h-old cultures of BUZ-14 suppressed brown rot by M. 397 
fructicola and M. laxa in peaches and also blue rot by P. expansum in apples but failed 398 
in the rest of the diseases (Table 5). The final concentration of iturin A in peaches 399 
achieved 1.6-1.8 µg g-1 and BUZ-14 populations reached 108 CFU g-1 whereas neither 400 
growth nor iturin A production was detected in the rest of the fruits. We could deduce 401 
that the amount of iturin A brought with the culture (36 ± 14 µg mL-1) could be enough 402 
to inhibit the growth of Monilinia species in peaches and P. expansum in apples, with 403 
MICs in vivo of 16.9 and 33.9 µg mL-1, respectively. However, this concentration was 404 
insufficient to control the rest of the pathogens (B. cinerea, P. digitatum and P. 405 
italicum). Thus, BUZ-14 cultures drastically prevent Monilinia spp. in peach fruit since 406 
the microorganism is able to grow and produce significant levels of iturin A but, as in 407 
the case of P. expansum, a cell free supernatant would also be effective. For the rest of 408 
the fruit-pathogen binomials where no growth of the BCA was detected, a more 409 
concentrated supernatant in iturin A would need to be tested in order to inhibit the 410 
diseases.  411 
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Improving our knowledge of the mechanisms of action of BCAs and their behaviour in 412 
planta could help to select the most efficient form of application (BCA cultures, BCA 413 
cultures enriched in a specific substance, CFS or iturin A enriched fractions). Finding a 414 
BCA able to grow and produce  a sufficiently active metabolite in planta could be the 415 
easiest and cheapest  application method but, as our results have shown, this behaviour 416 
is highly specific since it could be influenced by many conditions such as pH or 417 
temperature, and the available nutrients (Ashis and Kishore, 2005; Monteiro et al., 418 
2016). The use of CFS with the maximum concentration of active metabolites may have 419 
more advantages than cultures but the difficulty of determining its complex composition 420 
does not allow the innocuousness of its application to be established. On the other hand, 421 
formulating a cell free biopesticide enriched in one or various metabolites would require 422 
high production costs and yields, but toxicity assays may be easier. Many studies 423 
endorse the low toxicity of iturin A (Kim and Lee, 2009; Zhang et al., 2012; Dey et al., 424 
2016; Cao et al., 2017) but strict toxicological studies that guarantee its innocuousness 425 
for humans and the environment are essential for any future application. 426 
4. Conclusions  427 
The present study has shown that iturin A produced by B. amyloliquefaciens BUZ-14 is 428 
the main lipopeptide family responsible for fungal inhibition and which at low levels 429 
provides effective control of brown rot in peaches and blue mould in apples. Thus, a 430 
BCA that can produce a sufficiently active metabolite in planta could be the most 431 
suitable pathway for a commercial application. However, BUZ-14 is only able to grow 432 
and produce iturin A in peaches, which reveals the complex and specific nature of the 433 
BCA-fruit-pathogen interactions. For the rest of the fruit-pathogen binomials in which 434 
no growth of the BCA was detected, an iturin A enriched extract could be applied in 435 
order to obtain effective disease control. Thus, optimising the production of iturin A by 436 
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BUZ-14 and testing the antifungal efficacy of these enriched culture extracts will be the 437 
focus of our future research.  438 
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Figure captions 635 
Figure 1. Thin layer chromatography (TLC)-bioautography analysis of the lipopeptide 636 
fraction (LPF) of BUZ-14 after 96 h of incubation in 863 medium at 30 ºC. TLC plates 637 
A; B; C; D; E and F were covered with PDA inoculated with a fungal spore suspension 638 
at a concentration of 1-3 x 105 conidia mL-1 and incubated for 7 days at 25 ºC. A- M. 639 
fructicola; B- M. laxa; C- B. cinerea; D- P. italicum; E- P. expansum; F- P. digitatum. 640 
View in a fluorescence chamber at 254 nm of TLC three family spots (fengycin, iturin 641 
and surfactin). The inhibition zone for A, B, C, D, E and F can be observed at Rf=0.26. 642 
Figure 2. Comparison between MSE spectra from commercial Iturin (A) and the active 643 
compound from B.amyloliquefaciens BUZ 14 (B). (A) MSE spectra of the four peaks 644 
detected for m/z (1043.5562; 1057.5704; 1071.5900; 1085.5981). (B). MSE spectra 645 
obtained after scraping the active compound from TLC plates at 96 h of incubation 646 
time.  647 
Figure 3. Quantification of fengycin, surfactin and iturin produced by BUZ-14 in 863 648 
medium during the incubation time. Measurements of concentration were carried out 649 
following the lipopeptide extraction protocol at 24 h, 48 h, 72 h, 96 h and 120 h. 650 
Analytical standards were used as reference compounds. Data represent the average of 651 
three samples extracted on three different days ± SD. 652 
 653 
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Table 1. In vitro antifungal activity assayed by the well-dilution method in liquid medium of the Cell-Free Supernatant (CFS), the Lipopeptide 654 
Fraction (LPF) and the Non-Butanolic Fraction (NBF) produced by B. amyloliquefaciens BUZ-14 after 96 h of incubation at 30 ºC in 863 655 
medium against six postharvest fungal pathogens. Five replicates per pathogen and dilution were conducted on 3 different days.  656 
 657 
 658 
 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
a Non-growth of the fungal pathogen 671 
b
 Growth of the fungal pathogen 672 
Fraction Concentration 
(Dilution) 
B. cinerea M. fructicola M. laxa P. digitatum P. italicum P. expansum 
Lipopeptide 
fraction (LPF) 
1:6 NGa NG NG NG NG NG 
1:12 NG NG NG NG NG NG 
1:24 NG NG NG NG NG NG 
1:48 Gb NG NG G NG NG 
1:80 G G NG G G G 
1:100 G G NG G G G 
Non-butanolic 
fraction (NBF) 
1:6 NG NG NG NG G G 
1:12 G NG G G G G 
1:24 G G G G G G 
1:48 G G G G G G 
1:80 G G G G G G 
1:100 G G G G G G 
Cell-free 
supernatant (CFS) 
1:6 NG NG NG NG NG NG 
1:12 NG NG NG NG NG NG 
1:24 NG NG NG NG G G 
1:48 NG G NG G G G 
1:80 G G G G G G 
1:100 G G G G G G 
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Table 2. Percentage of reduction of the lesion diameter of B. cinerea in strawberries, M. fructicola and M. laxa in peaches, P. digitatum and P. 673 
italicum in mandarins and P. expansum in apples. The LPF and CFS were obtained from a 96 h-old culture of B. amyloliquefaciens BUZ-14 674 
incubated at 30 ºC in 863 medium. Fruits were stored at 20 ºC and 80 % R.H. for 5 days.  675 
 676 
 677 
 678 
 679 
 680 
 681 
aData are expressed as percentages of fungal growth inhibition compared with control fruits without treatment. Each value is the mean ± standard deviation of three replicates, 682 
done in 3 separate days, of 15 fruits each. 683 
bNo letter means no significant differences between fractions for the same phytopathogen and the same concentration. Different letters indicate significant differences at P < 684 
0.05 according to the Tukey test.685 
Fraction Concentration Reduction of lesion diameter (%)a 
B. cinerea M. fructicola M. laxa P. digitatum P. italicum P. expansum 
Lipopeptide 
fraction (LPF) 
1:6 72.6 ± 5.7b 100.0 ± 0.0 100.0 ± 0.0 9.5 ± 3.3 7.1 ± 2.1 100.0 ± 0.0 
1:12 31.6 ± 9.6 100.0 ± 0.0 100.0 ± 0.0 8.1 ± 3.1 6.4 ± 5.0 100.0 ± 0.0 
1:24 11.1 ± 4.8 100.0 ± 0.0 100.0 ± 0.0 7.1 ± 2.6 5.1 ± 2.5 16.0 ± 5.3 
 1:48 8.3 ± 3.5 75.3 ± 5.2ab 80.1 ± 3.9a 5.3 ± 2.4 4.2 ± 2.0 10.1 ± 4.1 
Cell-free 
supernatant 
(CFS) 
1:6 76.6 ± 4.4 100.0 ± 0.0 100.0 ± 0.0 13.2 ± 4.2 9.1 ± 4.1 100.0 ± 0.0 
1:12 24.0 ± 13.7 100.0 ± 0.0 100.0 ± 0.0 10.3 ± 3.5 8.3 ± 3.0 100.0 ± 0.0 
1:24 9.1 ± 5.4 100.0 ± 0.0 100.0 ± 0.0 8.6 ± 3.2a 7.9 ± 3.4 20.6 ± 4.1 
1:48 6.5 ± 2.6 90.3 ± 4.6b 92.1 ± 2.5b 5.2 ± 1.6 6.1 ± 1.9 16.3 ± 3.4 
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 686 
Table 3. Lipopeptides and isoforms of B. amyloliquefaciens BUZ-14 detected by LC-MS-MSE in 863 medium after 96 h of incubation at 30 ºC 687 
 688 
Lipopeptide                 Product and m/z observed         Assignment 
Surfactin 
  
1008.660;1030.642;1046.642 C13-surfactin [M+H,Na,K]+ 
1022.676;1044.660;1060.660 C14-surfactin [M+H,Na,K]+ 
1036.691;1058.676;1074.676 C15-surfactin [M+H,Na,K]+ 
Fengycin 
  
1463.804; 1485.804 C16-fengycin A [M+H,Na]+ 
1477.820;1499.799;1515.822 C17-fengycin A [M+H,Na,K]+ 
1491.804; 1529.804 C16-fengycin B [M+H,K]+ 
1505.814; 1527.804;1543.804 C17-fengycin B [M+H,Na,K]+ 
Iturin 
  
1043.5562;1065.5403;1082.4514 C14-iturin A [M+H,Na,K]+ 
1057.5704;1079.5516;1095.5531 C15-iturin A [M+H,Na,K]+ 
1071.5900;1093.5695;1110.5402 C16-iturin A [M+H,Na;K]+ 
1085.5981;1107.5704;1124.5570 C17-iturin A [M+H;Na;K]+ 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
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Table 4. Minimum Inhibitory Concentration of iturin A present on the LPF of B. amyloliquefaciens BUZ-14 obtained after 96 h of incubation at 697 
30 ºC in 863 medium for the six fungal pathogens tested.  698 
Phytopathogenic fungi Iturin A (µg mL-1)a 
In vitrob In vivoc 
B. cinerea 
M. fructicola  
M. laxa  
P. digitatum  
P. italicum  
P. expansum 
16.9 
8.5 
4.1 
16.9 
8.5 
8.5 
>  67.8 
16.9 
16.9 
>  67.8 
>  67.8 
33.9 
 699 
aLPF started at an iturin concentration of 407 µg mL-1 and was serially diluted by a factor of two until a concentration of 4.1 mg mL-1 was reached  700 
bIn vitro activity was assayed by the well-dilution method in liquid medium  701 
cIn vivo activity was tested by the puncture method: fruits were wounded with a sterile tip and 10 µL of the respective pathogen (104 conidia mL-1) was inoculated (B. cinerea 702 
in strawberries, M. fructicola and M. laxa in peaches, P. digitatum and P. italicum in mandarins and P. expansum in apples).  703 
 704 
 705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
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 714 
Table 5. Reduction 715 of the fungal growth, BUZ-14 counts and 
iturin A produced in 716 fruits after 7 days at 20 ºC. 
 717 
 718 
 719 
 720 
 721 
 722 
Data shown are means ± standard deviation. 723 
aInoculated with 10 µL of the respective pathogen (104 conidia mL-1) and 10 µL of a BUZ-14 24 h-old culture (108 CFU mL-1).  724 
b
 The percentage of inhibition of the disease was determined by measuring the lesion diameter in treated fruits and the control. 725 
cThe initial counts of BUZ-14 in the fruits were 5.0 log CFU g-1. 726 
dThe initial concentration of iturin A in the fruit tissue was 0.036 ± 0.014 µg g-1. These data were calculated from the iturin A concentration quantified in the 24 h-old cultures. 727 
end: not detected 728 
 729 
Fruit (fungal pathogen)a % inhibitionb BUZ-14 countsc                       
(log CFU g-1) 
Iturin Ad       
(µg g-1) 
Strawberries (B. cinerea) 15.4 ± 3.4  4.9 ± 0.5 nde 
Peach (M. fructicola) 100.0 ± 0.0  8.3 ± 0.7 1.8 ± 0.3  
Peach (M. laxa) 100.0 ± 0.0  8.6 ± 0.6 1.6 ± 0.5  
Mandarins  (P. digitatum) 8.4 ± 2.3  5.3 ± 0.4 nd 
Mandarins (P. italicum) 7.2 ± 2.4  5.1 ± 0.5 nd 
Apple (P. expansum) 100.0 ± 0.0  5.2 ± 0.4 nd 
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Highlights 1 
• Lipopeptides of BUZ-14 are the main metabolites for controlling postharvest 2 
rots 3 
• Iturin A is the key lipopeptide responsible for direct antibiosis 4 
• Only 17 and 34 µg mL-1 are necessary to suppress brown and blue rots, 5 
respectively 6 
• BUZ-14 is able to grow and produce significant iturin A in peaches 7 
• First report quantifying the production of iturin A in fruit 8 
